Rights and wrongs of <i>Helicobacter pylori</i> testing and treatment in children

Kakiuchi, Toshihiko

doi:10.1177/17562848231195251

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, there is controversy about the need for H. pylori eradication treatment when patients do not manifest any relevant symptoms due to the fact that it has been observed that in some cases the eradication of H. pylori is associated with the rise of other pathologies such as metabolic syndrome, gastroesophageal reflux disease (GERD) and its consequences, including esophageal and gastric cardia glandular malignancies [65][66][67]. In children, eradication is not recommended and other guidelines must be followed in order to manage the infection [68][69][70][71]. Besides that, H. pylori infection and treatments with virulence factors from this pathogen have been reported as an immunomodulatory with potential to mitigate symptoms for diseases such as inflammatory bowel disease and allergic airway diseases [72,73].…”

Section: Introductionmentioning

confidence: 99%

Bioactive peptides as alternative treatment for Helicobacter pylori infection

Franca-Oliveira,

Hernández-Ledesma,

Martinez-Rodriguez

2024

BCHD

View full text Add to dashboard Cite

The infection and chronic inflammatory response generated by Helicobacter pylori is a global health concern. This pathogen is characterized as a major risk factor in the development of gastric cancer and other diseases. Conventional eradication therapies are based on antibiotic regimens and as a consequence there is an increase in antimicrobial resistance of the pathogen strains, besides other potential side effects for the host. Therefore, it is necessary to explore new alternatives. This review delves into the realm of antimicrobial peptides, exploring their efficacy against H. pylori sourced from diverse origins. Furthermore, it sheds light on food-derived peptides exhibiting remarkable biological activity. These peptides exhibit promising effects on biomarkers associated with H. pylori infection, demonstrating anti-inflammatory and antioxidant properties validated through rigorous testing in both cell and animal models. Regarding the anti-inflammatory activity, the peptide VPY derived from soybean and the peptides derived from animal sources such as meat (β-Ala-His), egg (DEDTQAMPFR, DEDTQAMPF, MLGATSL, MSYSAGF, CR, FL, HC, LL, MK) and milk (IPAV) have reported a reduction of the cytokine IL-8, biomarker directly related to H. infection. For the antioxidant activity, peptides derived from milk (EAMAPK, AVPYPQ) and from Spirulina maxima (LDAVNR, MMLDF) have reduced ROS levels and could have a positive effect on the control of H. infection. Food-derived bioactive peptides with an anti-adhesive effect were also discussed. They derive from vegetable sources (corn, pea and wheat) and are capable of interacting with the host cells, interfering the adherence of H. pylori. Food-derived bioactive peptides have potential to avoid and/or mitigate undesired outcomes of infectious diseases due to the possibility of its application in nutraceuticals and food products, resulting in a preventive approach. Keywords: Helicobacter pylori, antibiotic resistance, bioactive peptides, antimicrobial peptides

show abstract